Compound class:
Synthetic organic
Comment: S4-1 is reported as a small molecule inhibitor of the PD-1/PD-L1 inhibitory immune checkpoint [1] that is exploited for cancer immunotherapy. It promotes dimerisation and internalisation of PD-L1 which reduces the opportunity of signaling via interaction with PD-1. As predicted, S4-1-induced PD-L1/PD-1 pathway blockade promotes T cell activation and reverses the immune inhibitory tumour microenvironment. In vivo, it has demonstrated anti-tumour effects in lung and colorectal cancer models (following intraperitoneal administration). Such small molecules are envisaged as alternatives to the existing anti-PD-L1 and anti-PD-1 monoclonal antibody therapeutics.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
((6-Methoxy-2-(2-methyl-[1,1′-biphenyl]-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)serine |
Database Links | |
GtoPdb PubChem SID | 479821112 |
PubChem CID | 166642489 |
Search Google for chemical match using the InChIKey | CUQPAAUFONWYPW-NRFANRHFSA-N |
Search Google for chemicals with the same backbone | CUQPAAUFONWYPW |
UniChem Compound Search for chemical match using the InChIKey | CUQPAAUFONWYPW-NRFANRHFSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | CUQPAAUFONWYPW-NRFANRHFSA-N |